GA-INSPIRE-BRANDS
17.1.2024 14:01:31 CET | Business Wire | Press release
Today, Inspire Brands announced two international franchise agreements to bring Jimmy John’s, the largest owned-delivery sandwich brand in the United States, to Canada and Latin America, launching the brand’s global expansion plan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117651076/en/
Jimmy John's international store concept design (Photo: Business Wire)
Jimmy John's focus on quality ingredients, convenience and digital innovation blended with ease of operations uniquely positions the brand for international appeal. Its global expansion will usher in a new way for international guests to enjoy its iconic menu—the ability to order hot, toasted sandwiches as a customization option.
"For 40 years, Jimmy John's has taken a straightforward approach to making ridiculously good, quality sandwiches and it's now time to share them with the world," said Michael Haley, President & Managing Director, International for Inspire Brands. “In a global restaurant environment where simplicity is paramount, we're confident this brand is primed for extensive international growth."
Jimmy John’s has reached agreements with two strong operators who both possess significant quick service restaurant experience and have established extensive footprints throughout Canada and Latin America.
- Foodtastic - A leading franchisor of restaurant brands in Canada, with more than 1,100 restaurants and $1.1 billion in sales.
- Franquicias Internacionales - Based in El Salvador, has a robust portfolio of several complementary businesses across food and beverage, digital media and logistics.
Jimmy John’s obsessive approach to culinary excellence and operational efficiency has helped fuel its growth in the U.S. and will be the foundation of the brand’s international expansion.
Quality Obsessed:
- Bread baked fresh in the restaurant throughout the day
- Premium meats and cheeses, as well as fresh vegetables that are hand-sliced in restaurants daily
Convenience Obsessed:
- Sandwiches, customized to your liking, made fresh and fast right when you want them
- Speedy accessibility via drive-thru, pick-up, and delivery
Technology Obsessed:
- Industry-leading mobile app and online ordering enabled through POS integration
- Exclusive rewards through the international loyalty program
While Jimmy John's is just embarking on its global journey, Inspire Brands is no stranger to international expansion. As a multi-brand restaurant company with more than 32,000 locations worldwide, including Arby's®, Baskin-Robbins®, Buffalo Wild Wings®, Dunkin'®, Jimmy John's® and SONIC®, Inspire has a robust international presence, with more than 9,900 locations.
Jimmy John's global expansion will be supported by Inspire's extensible, shared services platform and its international team, which has a wealth of experience managing and operating brands globally.
To learn more about growth opportunities with Jimmy John’s and Inspire, please visit inspirebrands.com/franchising/international/.
About Inspire Brands
Inspire Brands is a multi-brand restaurant company whose portfolio includes more than 32,000 Arby’s, Baskin-Robbins, Buffalo Wild Wings, Dunkin’, Jimmy John’s, and SONIC locations worldwide. The company was founded in 2018 and is headquartered in Atlanta, Georgia. For more information, visit InspireBrands.com.
About Jimmy John’s
Jimmy John’s, founded in 1983, is the largest owned delivery sandwich brand in the United States, with more than 2,600 restaurants in 48 states. Jimmy John’s is part of the Inspire Brands family of restaurants. For more information, visit JimmyJohns.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117651076/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom